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Patients with nonalcoholic fatty liver disease (NAFLD)
are reported to have low growth hormone (GH) pro-
duction and/or hepatic GH resistance. GH replacement
can resolve the fatty liver condition in diet-induced
obese rodents and in GH-deficient patients. However,
it remains to be determined whether this inhibitory
action of GH is due to direct regulation of hepatic lipid
metabolism. Therefore, an adult-onset, hepatocyte-
specific, GH receptor (GHR) knockdown (aLivGHRkd)
mouse was developed to model hepatic GH resistance
in humans that may occur after sexual maturation. Just
7 days after aLivGHRkd, hepatic de novo lipogenesis
(DNL) was increased in male and female chow-fed mice,
compared with GHR-intact littermate controls. How-
ever, hepatosteatosis developed only in male and
ovariectomized female aLivGHRkd mice. The increase
in DNL observed in aLivGHRkd mice was not asso-
ciated with hyperactivation of the pathway by which
insulin is classically considered to regulate DNL.
However, glucokinase mRNA and protein levels as
well as fructose-2,6-bisphosphate levels were in-
creased in aLivGHRkd mice, suggesting that en-
hanced glycolysis drives DNL in the GH-resistant
liver. These results demonstrate that hepatic GH
actions normally serve to inhibit DNL, where loss of
this inhibitory signal may explain, in part, the in-
appropriate increase in hepatic DNL observed in
NAFLD patients.
Patients with nonalcoholic fatty liver disease (NAFLD)
show a higher prevalence of insulin resistance, which is
characterized by increased fasting glucose and insulin
levels, as well as an increase in nonesterified fatty acids
(NEFAs) (1). NAFLD affects up to 30% of adults and
represents a high-risk factor in the progression to non-
alcoholic steatohepatitis, cirrhosis, and hepatocarcinoma
(2,3). Hepatic re-esterification of NEFA is considered
a major contributor to NAFLD (4,5). However, it is now
evident that increased de novo lipogenesis (DNL [i.e., the
production of new fatty acids from glucose]) (6) also plays
a significant role in progression to NAFLD (5,7–9), which
may in part be driven by hyperinsulinemia (1).
The liver is a major target of growth hormone (GH). GH
is required to maintain hepatic production of IGF-I, where
the liver is the primary source of circulating IGF-I (10). GH
and IGF-I work together to promote longitudinal growth
during the adolescent period and to support metabolic
function in adults (11). Circulating GH levels are reduced
by weight gain and decline progressively with age, indepen-
dent of weight (12–14). A reduction in circulating GH lev-
els or defects in hepatic GH signaling has been associated
with NAFLD (15). Specifically, subjects with primary GH
deficiency have a higher incidence of NAFLD, which can be
reversed with GH replacement therapy (16–18). Also, sub-
jects with inactivating mutations in the GH receptor
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(GHR; Laron Syndrome) have a higher incidence of NAFLD,
which cannot be reversed by IGF-I treatment (19), further
suggesting that GH plays a key role in regulating hepatic
lipid processing. The negative association between GH and
NAFLD is not limited to these rare conditions. In a large
cross-sectional study (20), individuals with lower GH levels
exhibited a higher prevalence of NAFLD. Since GH is re-
leased in a pulsatile and diurnal fashion, a single GH mea-
surement may not accurately represent the cumulative
amount of GH that has been released. Therefore, many
studies have used IGF-I as a surrogate marker of GH se-
cretion. These studies (21–25) demonstrate that circulating
levels of IGF-I are negatively associated with NAFLD. The
reduction in GH levels that occurs with weight gain and
obesity could certainly contribute to the low IGF-I levels
associated with NAFLD. However, the fact that IGF-I levels
remain significantly lower in individuals with NAFLD after
corrections for weight, waist circumference, and diabetes
(25) suggests that their livers are resistant to the actions
of GH. In fact, mice made obese by high-fat feeding fail to
respond to an acute injection of GH by increasing the level
of hepatic pStat5b (26), where the GHR/Jak2/Stat5b signal
transduction pathway is required for GH-mediated regula-
tion of IGF-I gene expression (27). In addition, rats fed
a high-fat, low-carbohydrate diet exhibited a decrease in he-
patic expression of the GHR (mRNA and protein), pStat5b
protein, and IGF-I mRNA levels (28). Hepatic insulin resis-
tance, which is characterized by impaired IRS/Akt inactiva-
tion of FOXO1, also could lead to hepatic GH resistance,
since FOXO1 has been shown to decrease hepatic GHR
expression (29).
The reduction in GH production/signaling and the sub-
sequent fall in IGF-I levels may not simply be the consequence
of NAFLD, but could actually contribute to the progression of
NAFLD, based on studies showing an increase in hepatic
triglyceride (TG) content in humans treated with the GHR
antagonist pegvisomant (30) and in mice expressing a GHR
antagonist (31). In fact, raising GH levels decreases hepatic
TG content in animal models of hepatosteatosis (32,33) as
well as in GH-deficient patients (16,17). However, questions
regarding how GH mediates this inhibitory effect still remain.
Therefore, our laboratory has conducted a series of studies to
address whether GH directly regulates hepatic fat produc-
tion/accumulation in adults. Specifically, a mouse model
was generated with adult-onset liver-specific GHR knock-
down (aLivGHRkd). The rate of hepatic DNL more than
doubled just 7 days after the induction of hepatic GH
resistance. The increase in DNL and hepatosteatosis in
aLivGHRkd mice was not associated with an increase in the
actions of insulin on the liver or with an increase in white
adipose tissue (WAT) lipolysis but was associated with end
points suggesting that glycolysis is enhanced.
RESEARCH DESIGN AND METHODS
Generation of aLivGHRkd and Littermate Controls
All mouse studies were approved by the Institutional Animal
Care and Use Committee of the Jesse Brown VA Medical
Center. C57BL/6J GHR-floxed (34) mice were housed in
a temperature-controlled (22–24°C) and humidity-controlled,
specific pathogen–free barrier facility with a 12-h light-
dark cycle (lights on at 0600 h) and were fed standard
laboratory rodent chow, unless otherwise indicated. The
10- to 12-week-old mice were injected in the lateral tail
vein with 100 mL saline containing 1.5 3 1011 genome
copies of an adeno-associated virus (AAV) bearing a liver-
specific thyroxine-binding globulin (TBG) promoter driving
a Cre recombinase transgene (AAV-TBGp-Cre, catalog
#AV-8-PV1091, AAV8.TBG.PI.Cre.rBG; Penn Vector Core,
University of Pennsylvania) or a null allele (AAV-TBGp-
Null, catalog #AV-8-PV0148, AAV8.TBG.PI.Null.bGH;
Penn Vector Core). TBGp is a hepatocyte-specific promoter
that allows the expression of Cre recombinase exclusively
in hepatocytes (Supplementary Fig. 1B–E), leading to re-
combination of the Ghr allele and knockdown of the
hepatic Ghr mRNA and protein (Fig. 1A and B and Supple-
mentary Figs. 1C and 2). The GHR-floxed littermate mice
injected with AAV-TBGp-Null served as controls. The
injection of AAV vectors did not increase levels of the in-
flammation markers (Supplementary Fig. 3). Mice were
killed 7 days after AAV injection.
Hormone and Metabolites
Plasma GH and insulin (Millipore, Billerica, MA), IGF-I
(Immunodiagnostic Systems, Gaithersburg, MD), ala-
nine aminotransferase (BioVision, Milpitas, CA), and
TG and NEFA (Wako Diagnostics, Richmond, VA) were
measured following the manufacturers’ instructions. He-
patic TG levels were measured after the extraction of
neutral lipids (35) using reagents obtained from Wako
Diagnostics. Hepatic glycogen was measured by the
Yale Metabolic Mouse Phenotyping Center (MMPC;
Yale School of Medicine, New Haven, CT). Hepatic fruc-
tose 2,6-bisphosphate (F2,6BP) was measured using the
method described by Van Schaftingen et al. (36). Hepatic
acyl-CoA species (acetyl-CoA, malonyl-CoA, b-hydroxybutyryl
[BHB]-CoA) were determined by liquid chromatography-
mass spectrometry (MS) at the MMPC of Case Western
Reserve University (Cleveland, OH).
Hepatic DNL
To measure hepatic DNL, food was removed at 0600 h, and
mice were injected at 1200 h with 30 mL/g body wt (BW)
0.9% NaCl deuterated water (2H2O; Sigma-Aldrich, Madi-
son, WI) to enrich body water up to 4%. Four hours later
(at 1600 h), mice were killed by cervical dislocation under
isoflurane anesthesia, and blood was collected from the in-
ferior cava into heparinized syringes (;50 mL). This condi-
tion represents the natural postabsorptive state of mice,
where mice consume,20% of their total food intake during
the day. Livers were collected and snap frozen in liquid
nitrogen. Blood and livers were sent to the Case Western
Reserve University MMPC for determination of the amount
of newly synthetized fatty acids bound to TG. Total TG-
bound fatty acids were isolated from tissues by chemical
hydrolysis and extraction procedures. The percentage of
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2H-labeled fatty acids was analyzed by gas chromatography-
MS. The 2H-labeled fatty acid (palmitate, stearate, or oleate)
covalently attached to glycerol indicates the amount of
new fatty acids. The contribution of DNL to the pool of
TG and palmitate was calculated using the following
equation: % 2H-labeled palmitate = [total 2H-labeled
palmitate 3 (2H-labeled body water 3 n) 2 1] 3 100,
where n is the number of exchangeable hydrogens, which
is assumed to be 22 (37,38), and 2H-labeled total body
water enrichment was measured from the blood collected
Figure 1—Phenotype of aLivGHRkd (Kd) mice. Hepatic Ghr mRNA (A), GHR protein (B), Igf1 mRNA (C), plasma IGF-I level (D), liver weight
(E ), glycogen (F), and TG content (G and H) in male and female mice. 320 Oil Red O–stained (I), 340 hematoxylin-eosin–stained (J), and
340 periodic acid Schiff–stained (K) liver sections of male control and aLivGHRkd mice. L–N: Oil Red O–stained liver sections of female
control and aLivGHRkd mice. H and L–N: Females were operated on at 8 weeks of age (sham surgery and OVX), a subset of OVX females
received a subcutaneous pellet with 17b-estradiol (E2), and 2 weeks later females were injected with AAV-TBGp-Null (controls [C]) or AAV-
TBGp-Cre (aLivGHRkd mice) and killed 7 days afterward. Asterisks indicate the difference between control and aLivGHRkd within group. H:
a, indicates difference between OVX-Kd and OVX-E2-Kd females. J and K, insets: Original magnification 3100. Arrow, fat filling; #,
glycogen deposition; nd, below the detection limit of the assay. *P < 0.05; **P < 0.01; ***P < 0.001. n = 4–7/group (males), 4–8/group
(females).
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from each mouse and determined using the acetone exchange
method and measured by gas chromatography-MS (39).
Ovariectomy
Eight- to nine-week-old GHR-floxed female mice under-
went sham operations or bilateral ovariectomy (OVX)
under isoflurane anesthesia. A subset of mice were
implanted (subcutaneously) with a slow-release pellet
containing 0.1 mg 17b-estradiol (catalog #SE-121; Inno-
vative Research of America, Sarasota, FL) at the time of
the OVX. Two weeks later, mice were injected with AAV-
TBGp-Null or AAV-TBGp-Cre in the lateral tail vein, and
females were killed 7 days later.
Assessment of Other Metabolic End Points
TG clearance was assessed in mice fasted overnight
(1700–0900 h) after an oral gavage of 200 mL of food-
grade olive oil (Oleoestepa, Estepa, Spain). The rate of
hepatic VLDL-TG secretion was assessed after tyloxapol
injection (500 mg/kg i.p.; Sigma-Aldrich). Glucose toler-
ance tests were performed in mice fasted overnight that
were injected with 2 mg glucose/g BW i.p. Insulin toler-
ance tests were performed in mice 4 h after food removal,
starting at 0700 h by injecting 1.5 mU insulin/g BW i.p.
(Novolin; Novo Nordisk, Bagsvaerd, Denmark). Blood
samples were taken from lateral tail vein, and blood glu-
cose measured (AlphaTRAK 2; Abbott Laboratories, Abbott
Park, IL). To assess ex vivo WAT lipolysis, 50–60 mg of
tissue from urogenital fat pads was washed in cold PBS
and minced into small pieces, then incubated in 500 mL
Krebs-Ringer HEPES buffer without or with 1 mmol/L
isoproterenol for 2 h at 37°C 5% CO2. Media were col-
lected to measure glycerol production (Free Glycerol Re-
agent; Sigma-Aldrich). Hepatic insulin sensitivity was
assessed in mice fasted overnight that were injected
with saline or 2 mU/g BW insulin i.p. Twenty minutes
later, the liver was collected for Western blot analysis.
Gene Expression Analysis
Tissues were processed as previously described (35). The
primers used for quantitative PCR are indicated in Sup-
plementary Table 3.
Western Blot
Livers were homogenized using buffers containing protease
inhibitors. Equal amounts of denatured proteins were
separated by SDS-PAGE gels (Bio-Rad), transferred to
nitrocellulose membranes, and incubated with the primary
and secondary antibodies shown in Supplementary Table 4.
Statistics
Two-tailed Student t tests were performed to analyze the
effect of aLivGHRkd, isoproterenol-stimulated lipolysis,
and insulin-mediated AKT phosphorylation. Two-way
ANOVA followed by Bonferroni post hoc test were per-
formed to compare glucose changes in response to glucose
and insulin tolerance tests, and TG changes after tyloxa-
pol injection or oral lipid loading. P values ,0.05 were
considered to be significant. All statistical analyses were
performed using Prism 5 (GraphPad Software, La Jolla, CA).
RESULTS
Knockdown of the Hepatic GHR in Adult Mice Rapidly
Leads to Fatty Liver in Males, While Estrogen Protects
Females From Lipid Accumulation
Treatment of adult GHR-floxed mice with a single in-
jection of AAV-TBGp-Cre resulted in liver-specific re-
combination of the Ghr allele (Supplementary Fig. 1C),
leading to aLivGHRkd, as confirmed by a dramatic reduc-
tion in Ghr mRNA and GHR protein levels, compared with
AAV-TBGp-Null–treated, GHR-floxed littermate controls
(Fig. 1A and B and Supplementary Fig. 2). Consistent
with the requirement for GH to maintain hepatic IGF-I
production, aLivGHRkd mice exhibited a reduction in he-
patic Igf1 mRNA and circulating IGF-I levels, compared
with controls (Fig. 1C and D). However, the suppression
of IGF-I in female aLivGHRkd mice was not as dramatic as
that observed in males, which may be due to the GH-
independent effects of estrogen (E2) on IGF-I expression
(40). Since IGF-I inhibits pituitary GH production, we
examined the expression of pituitary GH, GH-releasing
hormone receptor, and ghrelin receptor, and all were in-
creased in aLivGHRkd male mice, but not in female mice
(Supplementary Fig. 4). Nonetheless, these pituitary changes
did not lead to a significant increase in circulating GH
levels (Supplementary Fig. 4B).
Seven days after the induction of aLivGHRkd, liver
weight was increased in both male and female aLivGHRkd
mice that were maintained on a standard chow diet (Fig.
1E). Hepatic glycogen and TG content increased in male,
but not in female, aLivGHRkd mice (Fig. 1F, G, and I–K).
Since it has been reported that premenopausal women are
protected from NAFLD (41,42), and that ovary-intact
mice, but not OVX mice, are protected from diet-induced
fatty liver (43), we examined the impact of aLivGHRkd in
OVX mice, with and without E2 replacement (Fig. 1H and
L–N). Three weeks after the GHR-intact mice underwent
OVX, hepatic TG content did not differ from that in
sham-operated controls. However, the induction of
aLivGHRkd 2 weeks after the OVX doubled hepatic TG
content 1 week later, and this effect was blocked by es-
trogen replacement (Fig. 1H and L–N). Therefore, estro-
gen protects female mice from excess hepatic TG
accumulation induced by hepatic GH resistance.
Hepatic GH Resistance Increases DNL in Both Male
and Female Mice
A series of studies was conducted to identify the source of
excess TG accumulation in the livers of male aLivGHRkd
mice and to begin to explore why ovary-intact aLivGHRkd
female mice are protected. The rate of hepatic VLDL-TG
release, after the inhibition of systemic lipoprotein lipase
activity by tyloxapol, did not differ between aLivGHRkd
mice and controls (Fig. 2A). Also, the rate of TG clear-
ance after an oral gavage of olive oil was not altered by
aLivGHRkd (Fig. 2B). Although enhanced GH-mediated
WAT lipolytic activity is thought to contribute to fatty
liver in mouse models with congenital defects in hepatic
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GH signaling (44,45), we found no evidence to support
enhanced WAT lipolysis in aLivGHRkd mice. Specifically,
there was no increase in plasma NEFA levels under dif-
ferent conditions (Table 1 and 2 and Supplementary Table
2). Also there was no reduction in WAT subdepot weights
or alterations in WAT lipolytic/lipogenic gene expression
(Table 1). Consistent with these observations, ex vivo ex-
plants of WAT from aLivGHRkd mice did not release
more glycerol under basal or isoproterenol-stimulated con-
ditions (Fig. 2C and Supplementary Table 1 and 2). Taken
together, these results demonstrate that the increase in
hepatic TG observed in male aLivGHRkd mice is unlikely
to be due to a decrease in hepatic lipoprotein release,
increases in hepatic TG uptake, or re-esterification of
NEFA derived from peripheral sources.
Common to both males and females, hepatic GH
resistance more than doubled the rate of DNL (Fig. 2D
and Supplementary Fig. 5). These findings clearly demon-
strate that intact GHR signaling is required to suppress
hepatic DNL, independent of sex. The reason why females
are protected from hepatic TG accumulation, despite en-
hanced DNL, remains to be determined. However, recent
studies (46,47) suggest that estrogen promotes the flux of
lipids from the liver into adipose tissue stores. This would
be consistent with the observation that urogenital fat pad
weight increased in female aLivGHRkd mice, but not in
male aLivGHRkd mice (Table 1). In addition, circulating
TG levels increase in male aLivGHRkd mice, but not in
female aLivGHRkd mice (Supplementary Table 1 and 2).
Although intriguing, further studies are required to better
define these sexually dimorphic responses. Nonetheless,
given the profound phenotype observed in male mice af-
ter aLivGHRkd, subsequent studies used male mice to
begin to explore how GH regulates hepatic DNL.
The Canonical Pathway by Which Insulin Drives
Lipogenesis Is Not Enhanced by Hepatic GH
Resistance
Since insulin is a key driver of hepatic DNL through AKT-
mediated maturation of the lipogenic transcription factor
SREBP-1c (6), we examined the impact of short-term he-
patic GH resistance on circulating insulin levels, as well as
on systemic and hepatic insulin sensitivity. Insulin levels
did not differ from those of controls under conditions
used to study DNL (10 h after food removal starting at
0600 h; Table 2) or after an overnight fast (16 h after
food removal starting at 1700 h; Supplementary Table 2).
Figure 2—Potential sources of hepatic fat accumulation in
aLivGHRkd mice. A: Rate of hepatic VLDL-TG secretion after
tyloxapol injection (time 0, 500 mg/kg i.p.) in mice after 4-h food
removal starting at 0800 h. Plasma TG clearance after an oral gavage
of olive oil (200 mL) in mice fasted overnight (B), ex vivo basal and
1 mmol/L isoproterenol-stimulated urogenital-fat lipolysis assessed
by the amount of glycerol in the media (C), and the amount of newly
formed palmitate associated with TG as an indicator of DNL (D).
These measurements were performed in male (left) and intact-
female (right) control mice (dotted lines and open circles/columns)
and aLivGHRkdmice (solid lines and circles/columns). Asterisks indicate
differences between control and aLivGHRkd within the experiment; †
and ‡ indicate differences between basal and isoproterenol-stimulated
glycerol production within the group (C). *P < 0.05; **P < 0.01; †P =
0.0063; ‡P = 0.0006. n = 8–10/group (A and B); 7–8 males/group and
3 females/group (C); 6–9/group (D). C, controls.
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However, insulin was elevated under basal conditions (4 h
food removal starting at 0800 h; Supplementary Table 1)
but was not associated with systemic insulin resistance, as
measured by insulin or glucose tolerance tests (Fig. 3A
and B). In addition, hepatic levels of mature SREBP-1c
(mSREBP-1c) were not elevated and in fact were reduced
in the same conditions used to assess DNL (Fig. 3C). This
disconnect between insulin and mSREBP-1c could be
explained in part by the observation that insulin-mediated
phosphorylation of AKT was impaired in the livers of
aLivGHRkd mice (Fig. 3D). These results suggest that the
increased hepatic DNL rate in aLivGHRkd mice is not due
to hyperactivation of the canonical insulin signaling asso-
ciated with DNL.
Hepatic Gene Profile, Cytosolic Glucokinase, and
F2,6BP Levels Suggest Glycolysis Is Driving Enhanced
DNL in the GH-Resistant Liver
The expression of key genes and metabolites involved in
hepatic lipid and glucose metabolism, as illustrated in Fig.
4A (6), was measured in the same livers in which DNL was
evaluated, in order to ascertain the potential point of
control of enhanced DNL by hepatic GH resistance. Con-
sistent with the observation that levels of mSREBP-1c
were not increased, the expression of SREBP-1c lipogenic
target genes (acetyl-CoA cocarboxylase-1 [Acc-1], fatty
acid synthase [Fasn], and fatty acid elongase 6 [Elovl6])
was also not elevated above control levels (Fig. 4B). In-
terestingly, stearoyl-CoA desaturase-1 (Scd-1) expression
was dramatically increased in aLivGHRkd mice, where an
increase in SCD-1 activity has been shown to promote
DNL by decreasing the level of saturated fatty acids that
are known inhibitors of ACC-1 activity (48). In addition,
reduced carnitine palmitoyl-transferase 1a (Cpt1a) mRNA
(Fig. 4B) and BHB-CoA levels and a tendency (P = 0.06)
for lower plasma ketone levels (Fig. 4C and D) indicate
that fatty acid oxidation is suppressed in the aLivGHRkd
mice, which could contribute to the hepatic TG accumu-
lation. However, acetyl-CoA and malonyl-CoA levels were
normal or tended to be increased, respectively (Fig. 4E and F),
where malonyl-CoA may serve to suppress CPT1a activity (6).
Table 1—aLivGHRkd does not increase WAT lypolysis
Males Females
Control aLivGHRkd Control aLivGHRkd
Plasma NEFA (mEq/L) 1.06 6 0.12 1.15 6 0.11 1.07 6 0.12 1.13 6 0.09
Fat depot weight/BW
UG-fat 6.89 6 0.74 7.58 6 0.28 5.21 6 0.22 7.40 6 0.69*
RP-fat 1.81 6 0.36 2.01 6 0.19 3.53 6 0.24 4.58 6 0.80
SC-fat 4.55 6 0.56 4.24 6 0.30 6.44 6 0.28 7.03 6 0.67
Lipolytic genes mRNA
Hsl 100.00 6 2.56 111.31 6 4.30 100.00 6 19.57 109.06 6 13.70
Atgl 100.00 6 16.76 100.67 6 8.63 100.00 6 24.92 89.52 6 12.30
Adrb3 100.00 6 26.14 101.64 6 8.83 100.00 6 29.09 83.65 6 10.34
Lipogenic genes mRNA
SREBP-1c 100.00 6 12.19 97.50 6 7.36 100.00 6 23.13 101.58 6 19.13
Pparg 100.00 6 22.70 132.69 6 4.66 100.00 6 15.06 95.82 6 10.38
Fasn 100.00 6 18.55 118.11 6 26.93 100.00 6 21.69 92.76 6 27.34
Scd-1 100.00 6 18.06 103.36 6 8.20 100.00 6 18.22 92.62 6 22.21
Gpat 100.00 6 10.72 88.28 6 8.18 100.00 6 15.02 119.08 6 14.34
Dgat2 100.00 6 38.35 131.35 6 13.96 100.00 6 21.14 91.15 6 20.29
Data are reported as mean6 SEM. Plasma NEFA and WAT (unilateral subdepot mg/g BW3 103) weight and UG-WAT lipolytic/lipogenic
gene expression. Adrb3, adrenergic receptor b3; Atgl, adipose TG lipase; Dgat2, diacylglycerol O-acyltransferase 2; Gpat, glycerol-3-
phosphate acyltransferase; Hsl, hormone-sensitive lipase; Pparg, peroxisome proliferator–activated receptor g; RP, retroperitoneal; SC,
subcutaneous; UG, urogenital. *P , 0.05, differences between control and aLivGHRkd mice. Mice were killed 4 h after food removal
starting at 0800 h. Males and females were analyzed at separated times and they were not littermates; therefore, differences between
values for males and females should not be directly compared.
Table 2—Plasma NEFA and insulin levels in male and female control and aLivGHRkd mice
Males Females
Control aLivGHRkd Control aLivGHRkd
NEFA (mEq/L) 1.05 6 0.07 0.91 6 0.07 0.62 6 0.06 0.66 6 0.05
Insulin (ng/mL) 1.04 6 0.21 1.37 6 0.14 0.65 6 0.07 0.78 6 0.08
Data are reported as mean 6 SEM. Mice were killed 10 h after food removal at 0600 h. Blood was taken from the inferior cava vein.
Males and females were analyzed at separated times and they were not littermates; therefore, values between males and females
should not be directly compared. n = 7–8/group.
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In addition, the expression of the gluconeogenic gene phos-
phoenolpyruvate carboxykinase 1 (Pck-1) was suppressed
(Fig. 4B) and is consistent with previous reports (49) show-
ing that GH/JAK2/STAT5b directly stimulates hepatic
Pck-1 expression.
Normal acetyl-CoA levels in aLivGHRkd livers, in the
presence of enhanced DNL and suppressed fatty acid
oxidation/gluconeogenesis, suggest that glycolysis likely
provides carbons to maintain acetyl-CoA pools. Increased
expression of glucose uptake–related genes (Glut-2 and
glucokinase gene [Gck]; Fig. 4B) and total GCK protein
levels (Fig. 4G) suggest that glucose is taken up more
efficiently by the aLivGHRkd livers to feed the glycolytic
route and provide carbons for DNL.
Because the rate of glycolysis-driven DNL is highest
after a meal, the same gene panel measured in Fig. 4B was
measured in a different set of mice that were fasted over-
night and then fed with a standard chow diet for 6 h (Fig.
5A). The expression of Glut-2; Gck; pyruvate kinase liver
and red blood cell (Pklr); glucose-6-phosphatase, catalytic
(G6pc); Fasn; and Scd-1 was greater in refed aLivGHRkd
mice compared with refed controls. Of note, cytosolic
GCK protein levels remained elevated in aLivGHRkd in
both fasted and refed conditions (Fig. 5B). Since GCK is
active in the cytosol, it can be concluded that GCK activity
is sustained in the GH-resistant liver. Importantly, levels
of F2,6BP (Fig. 5C), the most potent activator of glycolysis
and inhibitor of gluconeogenesis (50), were increased in
aLivGHRkd livers. Taken together, these results suggest
that hepatic GH resistance enhances hepatic glucose up-
take (GCK) and glycolysis (F2,6BP), thereby supplying
a substrate for glycogenesis and DNL.
DISCUSSION
Existing literature cannot readily explain why GH protects
the adult liver from excess fat accumulation. It has been
previously reported (44,45,51–53) that mouse models
with congenital, liver-specific knockout of the GHR or
its downstream effectors (JAK2 and Stat5) develop hep-
atosteatosis as adults. In these mice, hepatosteatosis is
thought to be mediated by the indirect actions of GH
since circulating levels of IGF-I were reduced, leading to
a rise in GH, which is thought to drive systemic insulin
resistance and WAT lipolysis, thereby shifting the flux of
fatty acids to the liver, independent of changes in DNL
(45). However, mice with congenital liver-specific knock-
out of IGF-I (LID mice [54]) do not exhibit hepatosteato-
sis relative to intact controls, despite elevated GH levels
and systemic insulin resistance. In fact, the livers of LID
mice are protected from fat accumulation that develops
with age (55), suggesting GH may act directly on the liver to
block excessive fat accumulation. Unfortunately, the direct
effect of GH on hepatic metabolism is difficult to assess
using congenital models, in that low IGF-I/high GH levels
during development alter the development of other tissues,
including muscle, fat, and bone (44,54), which could indi-
rectly contribute to the adult metabolic phenotype.
To test the direct effect of GH on adult liver metabo-
lism, independent of the confounding factors that arise in
congenital knockout models, we generated a mouse model
with aLivGHRkd. In sharp contrast to previous models,
aLivGHRkd mice exhibit an increase in hepatic DNL sufficient
to increase hepatic TG content, independent of changes in
systemic insulin sensitivity or WAT lipolysis. These obser-
vations reveal, for the first time, that hepatic GHR is
critical to keep DNL under control in order to prevent
fatty liver development. Since NAFLD patients have low
GH production/signaling (21–25) as well as elevated DNL
(5,8), our current data suggest that the reduction in hepatic
GH action may directly contribute to inappropriate DNL in
this patient population.
Figure 3—Peripheral glucose homeostasis and hepatic insulin sensi-
tivity in male control and aLivGHRkd mice. Insulin tolerance tests (1.5
mU insulin/g BW i.p. in mice after 4 h of food removal) (A) and glucose
tolerance tests (2 mg glucose/g BW i.p. in mice after overnight food
removal) (B) of control (dotted lines) and aLivGHRkd (solid lines) mice.
C: Hepatic mSREBP-1c protein levels in mice after 10 or 4 h of food
removal of control (C) and aLivGHRkd (Kd) livers measured by Western
blot analysis using housekeeping proteins: b-tubulin for SREBP-1c
antibody C-20 and Sypro staining for SREBP-1c antibody H-160. D:
Insulin-mediated hepatic AKT phosphorylation (S473 and T308) in mice
fasted overnight 20 min after a bolus of 2 mU insulin/g BW i.p. mea-
sured by Western blot analysis. Asterisks indicate differences between
vehicle- and insulin-mediated AKT phosphorylation. † and ‡ indicate
difference between control and aLivGHRkd within experiment or within
insulin treatment. NS: nonspecific band. *P < 0.05; **P < 0.01; ***P <
0.001; †P< 0.05; ‡P < 0.001. n = 7–10/group (A and B); 5–6/group
(C ); 3/group (D). I, insulin; V, vehicle.
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Both male and female aLivGHRkd mice exhibited an
increase in hepatic DNL, but only males rapidly accumu-
lated lipids. The first reports examining the liver pheno-
type of mice with congenital hepatic GH signaling defects
focused on males and did not indicate any sex differences
(44,45,51). More recently, List et al. (56) reported that
female LivGHRKO mice accumulate less TG in the liver
when examined at 6 months of age, which is consistent
Figure 4—Hepatic gene expression profile and acyl-CoA, GCK, and plasma ketone levels in male control and aLivGHRkd mice, measured
in the same mice used to assess DNL. A: Diagram of key hepatic metabolic pathways. B: Hepatic gene expression in aLivGHRkd mice
(closed columns) relative to control mice (set at 100%, dotted line). Hepatic BHB-CoA (C), plasma ketones (3-HB or b-hydroxybutyrate) (D),
hepatic acetyl-CoA (E), malonyl-CoA (F ), and GCK protein (G) levels from control and aLivGHRkd male mice. Mice were killed 10 h after
food removal, starting at 0600 h. Asterisks indicate the differences between control and aLivGHRkd mice within the experiment. *P < 0.05;
**P < 0.01; ***P < 0.0001. n = 7–8 mice/group. C, control; Kd, aLivGHRkd; NF, normalization factor.
Figure 5—Hepatic gene expression profile and cytosolic GCK and F2,6BP levels in fasted and refed male control and aLivGHRkd mice.
A: Hepatic gene expression in aLivGHRkd (closed columns) mice relative to control mice 6 h after refeeding a standard chow diet, following an
overnight fast (1700–0800 h) (refed controls set at 100% as a dotted line). Hepatic cytosolic GCK protein (B) and F2,6BP (C) levels in mice after
an overnight fast or in 6-h refed mice following an overnight fast. Asterisks indicate the differences between control and aLivGHRkd within
experiment. a, indicates differences between fasted and refed mice within the group. *P < 0.05; **P < 0.01; a, P < 0.05. n = 4–6 mice/group.
NF, normalization factor.
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with our observations in aLivGHRkd mice. In the current
study, we found that intact ovary function and estrogen
protect female aLivGHRkd mice from excess hepatic fat
accumulation. These results are consistent with reports in-
dicating that premenopausal women show a lower preva-
lence of NAFLD, compared with postmenopausal women
and men (41,42), and ovaries (estrogen) protect female
mice from diet-induced hepatosteatosis (43,46,57). Estro-
gens may protect the liver from hepatic lipid accumulation
at multiple levels (47). Estrogen improves whole-body in-
sulin sensitivity in humans and rodents, favoring fat de-
position in adipose tissue (47). However, recent studies
(46) suggest that estrogen, acting through hepatic ERa,
blocks insulin-mediated suppression of hepatic TG secre-
tion, thereby reducing hepatic TG accumulation. Therefore,
estrogen may protect the female aLivGHRkd liver from
excessive fat accumulation by shifting the flux of newly
formed TG from the liver to the adipose tissue, as sup-
ported by our observation that urogenital fat pad weights
were increased in female aLivGHRkd mice. However, future
studies will be required to specifically test this hypothesis.
Despite the sexually dimorphic impact of aLivGHRkd
on hepatic TG accumulation, loss of hepatic GH signaling
clearly increased DNL in both male and female mice. GH
is commonly thought to antagonize the actions of insulin
(58). Therefore, it might be assumed that a reduction in GH
signaling would simply enhance the ability of insulin to
promote lipid production. However, in livers of aLivGHRkd
mice, proximal insulin signaling, SREBP-1c maturation, and
expression of SREBP-1c target genes (Acc-1, Fasn, Elovl6)
were not increased in association with enhanced DNL that
was measured in the postabsorptive state. Since SREBP-1c
is considered the canonical target of insulin-mediated
increases in hepatic TG production, the normal/low levels
of mSREBP-1c in aLivGHRkd mice suggest that GH acts
independently of classic insulin-mediated lipogenic path-
ways to modulate hepatic DNL.
Although the exact control points remain to be
established, three pieces of evidence suggest that glycol-
ysis is increased in the aLivGHRkd liver. First, the
increase in Gck mRNA levels was reflected by an increase
in total GCK protein levels, as well as by an increase in
cytosolic GCK protein levels (active form). An increase in
active GCK would trap glucose as glucose-6-phosphate to
favor glycolysis (6). Consistent with the increase in Gck
expression in the aLivGHRkd liver, it was observed that 2
days of GH treatment (intraperitoneally twice daily) sup-
pressed Gck mRNA in diet-induced obese male mice (E.O.
List, personal communication), where GH treatment ulti-
mately led to a reduction in hepatic TG content (33).
Second, the level of F2,6BP was increased in fasted and
refed aLivGHRkd mice. F2,6BP is a potent inhibitor of
fructose-1,6-bisphosphatase and an activator of phospho-
fructokinase-1, so an increase of F2,6BP levels would
serve to inhibit gluconeogenesis and promote glycolysis
(6). Third, the expression of Pklr and G6pc is increased in
aLivGHRkd livers after refeeding, above that observed in
refed controls. These genes are unique targets of carbohy-
drate response element–binding protein, where the carbo-
hydrate response element–binding protein requires glucose
metabolites produced during glycolysis for its activation
(6). These results, coupled with experimental and clinical
reports showing that overexpression or pharmacologic ac-
tivation of GCK can increase DNL and hepatic TG accumu-
lation (59,60) and that patients with NAFLD exhibit an
increase in Gck expression (61) and DNL (8), raise the
possibility that hepatic GH resistance might contribute to
NAFLD by increasing glycolysis-mediated DNL.
This study demonstrates for the first time that GH
directly regulates hepatic TG content by keeping DNL
under control. This information is highly translational
and provides a new molecular mechanism controlled by
GH in the liver, which may help in understanding how GH
therapy reverses NAFLD in individuals with GH deficiency
and may provide insight into an ongoing clinical trial
(Clinical trial reg. no. NCT02217345, clinicaltrials.gov)
examining whether low-dose GH therapy can reverse
NAFLD in the general population.
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